Article Figures & Data
- Table 1
ACS-verified level 1 trauma centers and the effect of COVID-19 on research activities
All
n=40Academic
n=34 (85%)Non-academic
n=6 (15%)Total responses Facility characteristics Type of facility 40 Academic 34 (85%) – – Non-academic 6 (15%) – – Profit status 39 Non-profit 32 (82%) 29 (88%) 3 (50%) For profit 2 (5%) 0 (0%) 2 (33%) Government 5 (13%) 4 (12%) 1 (17%) Part of a hospital system 34 (85%) 28 (82%) 6 (100%) 40 Total licensed beds (median (IQR), range) 509 (400–700), 249–1000 545 (400–710), 249–1000 440 (330–600), 250–800 38 Approximate adult trauma admissions in the past 12 months (median (IQR), range) 2300 (1500–3000), 1200–4800 2190 (1450–3100), 1200–4800 2450 (1500–3000), 1500–3100 38 Years of ACS level 1 verification (median (IQR), range) 20 (7–28), 1–36 20 (7–28), 1–36 14 (4–28), 3–30 40 Effects of the COVID-19 pandemic Trauma service admissions reduced during COVID-19 14 (52%) 11 (52%) 3 (50%) 27 Admission reductions to levels below those required for level 1 verification 2 (7%) 2 (10%) 0 (0%) 27 Scheduled for review during March to December 2020 14 (52%) 12 (57%) 2 (33%) 27 Resource diversion from research during COVID-19 12 (44%) 9 (43%) 3 (50%) 27 Consenting studies postponed during COVID-19 10 (37%) 7 (33%) 3 (50%) 27 Competing priorities during COVID-19 have made it difficult to fulfill level 1 requirements 10 (40%) 8 (42%) 2 (33%) 25 ACS, American College of Surgeons.
Supplementary Materials
Supplementary data
Additional Files
Supplementary Data
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.